Alan Brooks
Senior Vice President, Research Metagenomi Therapeutics
Alan Brooks is the Senior Vice President of Research at Metagenomi. He oversees the company’s in vivo therapeutic gene editing programs and brings more than 30 years of leadership experience in the biotech and pharmaceutical industries, specializing in drug discovery with a focus on gene therapies and gene editing.
Prior to joining Metagenomi in November 2019, Alan was a Principal Scientist at Casebia Therapeutics, where he initiated and led CRISPR/Cas9 genome editing projects for hematology. Before that, he led projects in gene therapy and protein therapeutics focused on hemophilia and rare hematological disorders during his 10 years at Bayer Healthcare.
Before joining Bayer, Alan worked at several biotech startups focusing on cardiovascular and neurological diseases.
Seminars
- Identifying strategic, regulatory, and technical barriers limiting gene editing therapeutics to rare, single-patient applications and exploring pathways to expand into larger patient populations
- Examining how industry leaders are navigating manufacturing challenges, clinical development efficiency, and regulatory alignment to make genome editing commercially viable across multiple indications
- Discussing the organizational capabilities, investment priorities, and platform design decisions required to transition from boutique therapies to scalable, multi-disease treatment models
- Demonstrating durable factor VIII expression enabling potentially curative one-time hemophilia a treatment strategies
- Establishing precise genome editing minimizing off-target activity supporting confident regulatory advancement toward clinical translation
- Leveraging proprietary metagenomics platforms expanding scalable therapeutic applications across secreted protein deficiencies beyond hemophilia
